Skip to main content

Table 4 Comparison of immune marker expression in TNBC and MBC samples

From: Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

Metaplastic breast carcinoma immune checkpoint markers
OutcomeLevelTNBC (n = 119)MBC (n = 27)Totalp value
Age at initial diagnosisMean (SD)51.9 (11.8)57.8 (15.3)53.0 (12.7)0.0281
CD8+% in stroma ≥ 10No25 (21.0%)6 (22.2%)31 (21.2%)1.0000
Yes94 (79.0%)21 (77.8%)115 (78.8%)0.2451
CD8+% in tumor ≥ 10No66 (55.5%)22 (81.5%)88 (60.3%)0.0158
Yes53 (44.5%)5 (18.5%)58 (39.7%)
CD163+% in tumor ≥ 10No64 (53.8%)14 (51.9%)78 (53.4%)1.0000
Yes55 (46.2%)13 (48.1%)68 (46.6%)0.0765
CD163+% in stroma ≥ 10No24 (20.2%)1 (3.7%)25 (17.1%)0.0468
Yes95 (79.8%)26 (96.3%)121 (82.9%)
PD-L1% in tumor ≥ 1No107 (89.9%)19 (70.4%)126 (86.3%)0.0133
Yes12 (10.1%)8 (29.6%)20 (13.7%)
PD-L1% in stroma ≥ 1No32 (26.9%)11 (40.7%)43 (29.5%)0.1665
Yes87 (73.1%)16 (59.3%)103 (70.5%)
PD-L1% overall ≥ 1No32 (26.9%)12 (44.4%)44 (30.1%)0.1025
Yes87 (73.1%)15 (55.6%)102 (69.9%)
  1. TNBC samples were obtained from a different cohort of patients. p values from a two-sample t-test for continuous variables and a Fisher’s exact test for categorical variables. Abbreviations: MBC = metaplastic breast cancer; SD = standard deviation; TNBC = triple-negative breast cancer